Mark VandenBranden

Université Libre de Bruxelles — Belgium

Pharmacology, Toxicology and Pharmaceutics · Life Sciences

24h-index3.7kcitations28works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Pharmacogenetics and Drug Metabolism(26), Drug Transport and Resistance Mechanisms(14), Chemical Reactions and Isotopes(4), Inflammatory mediators and NSAID effects(3), Analytical Chemistry and Chromatography(3)

Publications28 total

Cationic lipid/DNA complexes induce TNF-α secretion in splenic macrophages
European Journal of Pharmaceutics and Biopharmaceutics·2008· 9 cited
Effect of tadalafil on cytochrome P450 3A4?mediated clearance: Studies in vitro and in vivo
Clinical Pharmacology & Therapeutics·2005· 87 cited
Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome
Journal of Pharmacology and Experimental Therapeutics·2004· 55 cited
Identification of the Human Cytochromes P450 Responsible for in Vitro Formation of R- and S-Norfluoxetine
Journal of Pharmacology and Experimental Therapeutics·2001· 96 cited
Tissue distribution and interindividual variation in human UDP-glucuronosyltransferase activity: relationship between UGT1A1 promoter genotype and variability in a liver bank
Pharmacogenetics·2000· 132 cited
In Vitro Glucuronidation Using Human Liver Microsomes and The Pore-Forming Peptide Alamethicin
Drug Metabolism and Disposition·2000· 339 cited
Three-Dimensional Quantitative Structure Activity Relationship Analyses of Substrates for CYP2B6
Journal of Pharmacology and Experimental Therapeutics·1999· 104 cited
Alterations of the catalytic activities of drug-metabolizing enzymes in cultures of human liver slices.
PubMed·1998· 45 cited
Further Characterization of the Expression in Liver and Catalytic Activity of CYP2B6
Journal of Pharmacology and Experimental Therapeutics·1998· 179 cited
Liquid chromatography/nuclear magnetic resonance spectroscopy and liquid chromatography/mass spectrometry identification of novel metabolites of the multidrug resistance modulator LY335979 in rat bile and human liver microsomal incubations.
PubMed·1998· 40 cited
Liver Dihydropyrimidine Dehydrogenase Activity in Human, Cynomolgus Monkey, Rhesus Monkey, Dog, Rat and Mouse
Pharmacology·1998· 12 cited
Examination of purported probes of human CYP2B6
Pharmacogenetics·1997· 93 cited
The human drug metabolizing cytochromes P450
Journal of Pharmacokinetics and Biopharmaceutics·1996· 165 cited
Bimodal distribution of renal cytochrome P450 3A activity in humans.
Molecular Pharmacology·1996· 181 cited
<i>In vitro</i>interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A
British Journal of Clinical Pharmacology·1996· 103 cited
Interaction of human liver cytochromes P450 in vitro with LY307640, a gastric proton pump inhibitor
Pharmacogenetics·1996· 90 cited
Comparisons of phase I and phase II in vitro hepatic enzyme activities of human, dog, rhesus monkey, and cynomolgus monkey.
Drug Metabolism and Disposition·1995· 168 cited
The Use of In Vitro Metabolism Techniques in the Planning and Interpretation of Drug Safety Studies
Toxicologic Pathology·1995· 81 cited
Relationships between the levels of cytochrome P4502C9 and its prototypic catalytic activities in human liver microsomes.
Drug Metabolism and Disposition·1994· 46 cited
Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily
Biochemical Pharmacology·1994· 396 cited
page 1 of 2Next →

Frequent Co-authors

Steven Wrighton(22), Barbara J. Ring(11), Jennifer S. Gillespie(6), Stephen D. Hall(4), Sean Ekins(4), S N Binkley(4), Jeffrey Stevens(3), Michael B. Fisher(2), Paul B. Watkins(2), Lisa A. Shipley(2), John R. Cashman(2), Allan E. Rettie(2), B J Ring(2), S A Wrighton(2), Lisa A. Shipley(2), James A. Eckstein(2), Charles B. Jensen(2), W. Brian(1), Mehmet Akif Sari(1), M. Iwasaki(1)